Toll Free: 1-888-928-9744

Hypothyroidism - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 30 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hypothyroidism - Pipeline Review, H1 2016


Global Markets Direct's, 'Hypothyroidism - Pipeline Review, H1 2016', provides an overview of the Hypothyroidism pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hypothyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Hypothyroidism
- The report reviews pipeline therapeutics for Hypothyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hypothyroidism therapeutics and enlists all their major and minor projects
- The report assesses Hypothyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hypothyroidism

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hypothyroidism
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypothyroidism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hypothyroidism Overview 7 Therapeutics Development 8 Pipeline Products for Hypothyroidism - Overview 8 Hypothyroidism - Therapeutics under Development by Companies 9 Hypothyroidism - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Hypothyroidism - Products under Development by Companies 12 Hypothyroidism - Companies Involved in Therapeutics Development 13 Synthonics, Inc. 13 Titan Pharmaceuticals, Inc. 14 Hypothyroidism - Therapeutics Assessment 15 Assessment by Monotherapy Products 15 Assessment by Combination Products 16 Assessment by Target 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Drug Profiles 22 (levothyroxine + liothyronine) - Drug Profile 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 BCT-305 - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 levothyroxine sodium SR - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 liothyronine sodium - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 liothyronine sodium SR - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecule to Agonize Thyroid Hormone Receptor for Hypothyroidism - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Hypothyroidism - Dormant Projects 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 29 Disclaimer 30
List of Tables
Number of Products under Development for Hypothyroidism, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Hypothyroidism - Pipeline by Synthonics, Inc., H1 2016 13 Hypothyroidism - Pipeline by Titan Pharmaceuticals, Inc., H1 2016 14 Assessment by Monotherapy Products, H1 2016 15 Assessment by Combination Products, H1 2016 16 Number of Products by Stage and Target, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 18 Number of Products by Stage and Route of Administration, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 21 Hypothyroidism - Dormant Projects, H1 2016 28

List of Figures
Number of Products under Development for Hypothyroidism, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Assessment by Monotherapy Products, H1 2016 15 Number of Products by Stage and Targets, H1 2016 17 Number of Products by Stage and Mechanism of Actions, H1 2016 18 Number of Products by Routes of Administration, H1 2016 19 Number of Products by Stage and Routes of Administration, H1 2016 19 Number of Products by Stage and Molecule Types, H1 2016 21

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin


Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to


Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv


Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant


Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.